New algorithm is offered on Siemens’ SOMATOM Force CT system.
The U.S. Food and Drug Administration (FDA) has given 510(k) clearance for a new image reconstruction algorithm for CT developed by Siemens.
The Advanced Model Iterative Reconstruction (ADMIRE) supplements Siemens’ Sinogram Affirmed Iterative Reconstruction (SAFIRE), which is a raw-data based iterative reconstruction algorithm that can provide dose reduction of up to 60 percent, according to a release. Siemens states that image quality, which usually tends to worsen with lower dose, can result in images with a natural image impression and improved reconstructed image quality with ADMIRE.[[{"type":"media","view_mode":"media_crop","fid":"27102","attributes":{"alt":"","class":"media-image media-image-right","id":"media_crop_8598634534260","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"2604","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"height: 66px; width: 100px; border-width: 0px; border-style: solid; margin: 1px; float: right;","title":" ","typeof":"foaf:Image"}}]]
ADMIRE is offered in Siemens’ SOMATOM Force, a dual-source CT system, and uses additional modeling loops that help deliver improved resolution at high contrast edges, resulting in the ability to deliver many studies at previously unachievable low-dose imaging, the release said.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.